What changed: Anaplastic thyroid cancer
Every dated change on the records linked to Anaplastic thyroid cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Approval2Milestone3This record1
September 2026 · 1
2020 · 1
2018 · 1
2014 · 2
- 2014ApprovalDabrafenibDabrafenib approved in US
With trametinib: BRAF V600E/K metastatic melanoma; later adjuvant melanoma, BRAF V600E NSCLC, anaplastic thyroid cancer, tumour-agnostic solid tumours and paediatric low-grade glioma
- 2014ApprovalTrametinibTrametinib approved in US
With dabrafenib: metastatic melanoma; later adjuvant melanoma, NSCLC, anaplastic thyroid cancer, tumour-agnostic BRAF V600E solid tumours, paediatric low-grade glioma